Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti-myeloma therapy is unclear. This meta-analysis included 2340 newly diagnosed MM pat... ...

请注册登录后继续浏览